Want to join the conversation?
Biopharmaceutical company $BXLT said it has launched ADYNOVATE, a new treatment to control bleeding episodes in adult patients with Hemophilia A with a simple twice-weekly dosing schedule, in the U.S. Market. ADYNOVATE was developed through a collaboration with $NKTR and was approved by U.S. FDA in Nov. 2015.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!